Trial · NCT01711879
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Adverse Events | 2 year | Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the incidence of adverse events |
| Primary | Severity of Adverse Events | 2 year | Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the severity of adverse events |
| Secondary | Rate and Extent of Resolution of Neovascularization | 1 year | Compare between Groups A and B the Rate and extent of resolution of neovascularization in patients with NVG Stages 1 \& 2. |
| Secondary | Intraocular Pressure (mmHg) at Baseline | Baseline | Intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B |
| Secondary | Intraocular Pressure (mmHg) at Week 52 | Week 52 | Mean intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B |
| Secondary | Number of Patients Losing > 5 Letters on Visual Acuity in Each Group A and Group B | Baseline to Week 52 | Comparison between patients, groups A and B, that lost \> 5 letters on visual acuity |
| Secondary | Number of Patients in Each, Group A and Group B, Gaining > 5 Letters on Visual Acuity | Baseline to Week 52 | Comparison of patients in each, group A and group B, that gained \> 5 letters on visual acuity |
| Secondary | Visual Acuity at Baseline | Baseline | Comparison of visual acuity between groups A and B |
| Secondary | Visual Acuity at Week 52 | Week 52 | Comparison of visual acuity at Week 52 between groups A and B |
| Secondary | Comparison of the Visual Field Between Groups | 1 year | Comparison of the Visual field s measured by HVF 24-2 SITA Standards between groups A and B |
| Secondary | Measure of the Optical Coherence Tomography(OCT) Outcomes | Baseline to Week 52 | Evaluation of the Optical Coherence Tomography(OCT) outcomes (average retinal nerve fiber layer(RNFL) and central macular thickness), Compared between groups A and B. |
| Secondary | Number of Patients With Need for Surgical Intervention | 1 year | Comparison between groups A and B and the need for surgical intervention in both arms during the follow-up period |
| Secondary | Number of Participants With Need for Additional IOP Lowering Medications | 1 year | Comparison between groups A and B for the need of additional IOP lowering medications |
| Secondary | Extent of Resolution of Neovascularization Between Groups | 1 year | Comparison of groups A and B and the extent of resolution of neovascularization in patients with NVG Stages 1 \& 2 |
| Secondary | Evaluation of the Average Retinal Nerve Fiber Layer (RNFL) | 1 year | Comparison between groups A and B of the average retinal nerve fiber layer (RNFL) as measured by Optical Coherence Tomography (OCT) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01711879/registered